Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).

On November 28, 2025 the company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share (the Nasdaq closing price on the grant date).

The restricted stock units vest over four years with 25% vesting each anniversary of the first day of the month after the grant. Options have a 10-year term and a four-year vesting schedule: 25% at the first anniversary and 12.5% every six months thereafter, subject to continued service.

Argus Dec 4 session

-0.84% close to close Open Argus

Details

News Market Reaction – INSM

In the Dec 4 session, INSM declined 0.84%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines standard inducement equity awards tied to new hires, with 44,273 restrict...

Analysis

This announcement outlines standard inducement equity awards tied to new hires, with 44,273 restricted stock units and 2,490 options granted at an exercise price of $207.77. The multi‑year vesting schedules and 10‑year option term align with typical retention structures under Nasdaq Listing Rule 5635(c)(4). In context of recent EU approval for BRINSUPRI and ongoing conference activity, this filing mainly reflects compensation governance rather than a change in Insmed’s operating or clinical trajectory.

Key Figures

New employees: 92 employees Restricted stock units: 44,273 RSUs Stock options granted: 2,490 options +5 more

New employees

92 employees

Recipients of inducement awards under 2025 Inducement Plan

Restricted stock units

44,273 RSUs

Granted on November 28, 2025 as inducement awards

Stock options granted

2,490 options

Aggregate options to purchase Insmed common stock

Exercise price

$207.77 per share

Option strike equal to Nasdaq closing price on grant date

RSU vesting period

4 years

25% of each RSU grant vests on each annual anniversary

Option term

10 years

Contractual life of inducement stock options

Initial option vesting

25% at first anniversary

Based on first day of month following grant date

Subsequent option vesting

12.5% every six months

Semiannual vesting until fourth anniversary

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   Scientific presentations

   24h Move

   -1.2%

   ERS Congress abstracts for TPIP and brensocatib across multiple sessions.

2. Dec 04

   Inducement grants

   24h Move

   -0.8%

   Equity inducement awards to new employees under Nasdaq Rule 5635(c)(4).

3. Nov 18

   EU drug approval

   24h Move

   +2.1%

   EU approval of BRINSUPRI for NCFB after accelerated assessment.

4. Nov 13

   CSR initiative

   24h Move

   -1.8%

   Global Day of Good mobilizing over 1,200 employees for volunteering.

5. Nov 05

   Investor conferences

   24h Move

   +2.3%

   Management presentations at two healthcare investor conferences with webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Nasdaq Listing Rule 5635(c)(4), inducement awards, restricted stock units, exercise price, +1 more

5 terms

Nasdaq Listing Rule 5635(c)(4) regulatory

"intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"today announced the granting of inducement awards to 92 new employees"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

restricted stock units financial

"the employees received 44,273 restricted stock units and options to purchase"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase an aggregate 2,490 shares ... at an exercise price of $207.77 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting schedule financial

"The restricted stock units have a four-year vesting schedule, with 25% of the shares"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 92 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on November 28, 2025, the employees received 44,273 restricted stock units and options to purchase an aggregate 2,490 shares of Insmed common stock at an exercise price of $207.77 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302632304.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many employees received inducement awards from Insmed (INSM) on November 28, 2025?

Insmed granted inducement awards to 92 new employees on November 28, 2025.

What equity did Insmed (INSM) grant under the 2025 Inducement Plan?

The company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share.

What is the vesting schedule for Insmed (INSM) restricted stock units granted as inducements?

The restricted stock units vest over four years, with 25% vesting on each anniversary of the first day of the month after the grant date, subject to continued service.

What are the terms and vesting for the inducement stock options from Insmed (INSM)?

Options have a 10-year term; vesting is 25% at the first anniversary of the first day of the month after grant and then 12.5% every six months through year four, subject to continued service.

Does Insmed (INSM) disclose the dilutive impact of the inducement grants?

The announcement lists total RSUs and option shares but does not disclose the percentage dilutive impact versus outstanding shares.

Why were the awards granted under Insmed's 2025 Inducement Plan?

The awards were made as material inducements to each employee's commencement of employment and were approved by the company's compensation committee under Nasdaq Listing Rule 5635(c)(4).